

- [14] Ning Y, Kong F, **Cragun JM**, Zheng W. Struma ovarii simulating ovarian sertoli cell tumor: a case report with literature review. *Int J Clin Exp Pathol* 2013;6(3):516-20.
- [13] Chambers SK, Chow SH, Janicek MF, **Cragun JM**, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Abu Shahin N, Alberts DS. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. *Clin Cancer Res* 2012 May 1;18(9):2668-78. Epub 2012 Mar 15. *Highlighted in May 1, 2012 Clin Cancer Res.*
- [12] **Cragun JM**. Screening for Ovarian Cancer. *Cancer Control: J of the Moffitt Cancer Center.* 2011;18(1):16-21.
- [11] Kamath SG, Chen N, Xiong Y, Wehnam R, Apte S, Humphrey M, **Cragun J**, Lancaster JM. Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation. *Int J Gynecol Cancer.* 2009;19(9):1564-9.
- [10] **Cragun JM**, Ellestad SC, Panni MK. Aminiotic fluid embolism presenting after uterine manipulation under general anesthesia: a case with a positive outcome. *Resuscitation.* 2008;77(1):145-6.
- [9] Havrilesky LJ, **Cragun JM**, Calingaert B, Alvarez Secord A, Valea FA, Clarke-Pearson DL, Berchuck A, Soper JT. The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. *Gynecol Oncol.* 2007;104(2):401-5.
- [8] Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, **Cragun J**, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Genomic signatures to guide the use of chemotherapeutics. *Nat Med.* 2006;12(11):1294-300.
Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, **Cragun J**, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Corrigenda: Genomic signatures to guide the use of chemotherapeutics. *Nat Med.* 2007;13(11):1388.
Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, **Cragun J**, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Retraction: Genomic signatures to guide the use of chemotherapeutics. *Nat Med.* 2011;17(1):135.
- [7] Lancaster JM, Dressman HK, Clare JP, Sayer RA, Martino MA, **Cragun JM**, Henriott AH, Gray J, Sutphen R, Elahi A, Whitaker RS, West M, Marks JR, Nevins JR, Berchuck A. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. *Int J Gynecol Cancer.* 2006;16(5):1733-45.
- [6] Lutman CV, Havrilesky LJ, **Cragun JM**, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT. Pelvic lymph node count is important prognostic variable for FIGO grade I and II endometrial carcinoma with high-risk histology. *Gynecol Oncol.* 2006;102(1):92-7.
- [5] Havrilesky LJ, **Cragun JM**, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Resection of lymph node metastasis influence survival in stage IIIC endometrial cancer. *Gynecol Oncol.* 2005;99(3):689-95.
- [4] Martino M, Balar A, **Cragun JM**, Hoffman MS. Delayed treatment of invasive cervical cancer due to intimate partner violence. *Gynecol Oncol.* 2005; 99(2): 507-9.
- [3] Chen L, Li L, Goldgof D, George F, Chen Z, Rao A, **Cragun J**, Sutphen R, Lancaster J. Improving reliability of response prediction to platinum-based therapy by AdaBoost and multiple classifiers. *Conf Proc IEEE Eng Med Biol Soc.* 2005;5:4822-5.
- [2] Li L, Chen L, Goldgof D, George F, Chen Z, Rao A, **Cragun J**, Sutphen R, Lancaster J. Integration of clinical information and gene expression profiles for prediction of chemo-response for ovarian cancer. *Conf Proc IEEE Eng Med Biol Soc.* 2005;5:4818-21.
- [1] **Cragun JM**, Havrilesky L, Calingaert B, Synan I, Secord A, Soper J, Clarke-Pearson D, Berchuck A. Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer. *J Clin Oncol.* 2005;23(16):3668-75.